
Opinion|Videos|November 19, 2025
Ongoing Research to Watch in TNBC
Panelists spotlight key trials and drugs to watch in ongoing research in triple-negative breast cancer.
Advertisement
Episodes in this series

The panel concludes by highlighting pivotal ongoing trials and investigational agents shaping the future of TNBC care. Areas of focus include next-generation ADCs, bispecific antibodies, and novel immunotherapy combinations designed to overcome resistance. Panelists also underscore the need for improved biomarker discovery, especially to identify which patients benefit most from immunotherapy or ADC-based regimens. They note that the TNBC research field is entering a dynamic phase where rational combination strategies and earlier intervention with effective agents could significantly improve patient outcomes.
Advertisement
Related to this article

The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.

The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.

The FDA granted fast track designation to PSV359 for locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors.

Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.

Surgeons at the UC San Francisco have performed over 25,000 robotically assisted minimally invasive surgeries.

Natera’s blood-based, cell-free DNA multi-cancer early detection assay received the designation after the FDA reviewed data spanning 12 cancer types.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 10/4/2026
2
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
3
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
4
FDA Flashback: Hematologic Cancer Decisions and News From September 2026
5


